M.B.A., MIT Sloan School of Management; M.S., biomedical engineering, and B.S., computational and systems biology, University of California, Los Angeles
Summary of Experience
Ms. Lu specializes in conducting complex economic analyses, primarily in health care litigation and health economics and outcomes research (HEOR). She has supported clients on issues related to alleged kickbacks, off-label marketing, and delayed generic entry, and assisted affiliated experts in the preparation of reports, testimony, and related analyses in connection with class certification, liability, and damages. Ms. Lu has extensive experience managing complex projects and analyzing large datasets, including government and private administrative claims records and clinical data. In her HEOR work, she has designed a model to estimate the value of a COVID-19 vaccine and conducted a landscape assessment for a multi-targeted novel therapy. Prior to joining Analysis Group, Ms. Lu worked in pharmacokinetics and drug metabolism research for Phases II and III clinical trials at Amgen.
Journal of Medical Economics, 2022
Increasing COVID-19 vaccination in the United States: projected impact on cases, hospitalizations, and deaths by age and racial group
Public Health, 2022